Roche and Aspen Agree to Produce Influenza Antiviral for Africa
Roche (Basel, Switzerland) has entered into a nonexclusive agreement with Aspen Pharmacare (Port Elizabeth, South Africa) to speed up production and supply of a generic version of oseltamivir ("Tamiflu") for Africa.
Roche (Basel, Switzerland, www.roche.com) entered into a nonexclusiveagreement with Aspen Pharmacare (Port Elizabeth, South Africa, www.aspenpharma.com)to speed up production and supply of a generic version of oseltamivir("Tamiflu") for Africa. The partnership is part of Roche's continuedefforts to boost availability of the antiviral to combat influenzaworldwide and prepare for an influenza pandemic.
In addition to providing the active pharmaceutical ingredient, Rochewill lend its technical expertise to assist Aspen in the manufactureand registration processes.
Roche already is working with other third parties to increase theproduction of its Tamiflu neuraminidase blocker and claims to be in theposition to manufacture 400 million treatments annually by the end ofthis year. The company also reports to be on schedule for meeting allorders from African governments by early 2007.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
